MIFH
RCKT icon

Migdal Insurance & Financial Holdings’s Rocket Pharmaceuticals RCKT Stock Holding History

Migdal Insurance & Financial Holdings’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-20,093
Closed -$892K – 657
2021
Q1 		$892K Buy
20,093
+12,469
+164% +$685K 0.01% 255
2020
Q4 		$418K Buy
+7,624
New +$278K ﹤0.01% 235

Other funds holding RCKT

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Migdal Insurance & Financial Holdings's RCKT Position: Q2 2021 in Review

Migdal Insurance & Financial Holdings sold out of Rocket Pharmaceuticals (RCKT) in Q2 2021, closing a stake of 20,093 shares — an estimated $892K sold.

Migdal Insurance & Financial Holdings first reported a position in RCKT in Q4 2020 and held it in 2 quarters. The position peaked at $892K in Q1 2021. 150 funds tracked by Wall St. Rank hold RCKT as of Q2 2021.

  • Migdal Insurance & Financial Holdings reported no remaining Rocket Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Migdal Insurance & Financial Holdings sold 20,093 Rocket Pharmaceuticals shares in Q2 2021, an estimated $892K.
  • Migdal Insurance & Financial Holdings first reported a position in Rocket Pharmaceuticals in Q4 2020 and held it in 2 quarters.
  • Migdal Insurance & Financial Holdings's Rocket Pharmaceuticals position peaked at $892K in Q1 2021.
  • 150 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2021.

Based on Migdal Insurance & Financial Holdings's 13F filing for Q2 2021, filed 4 Aug 2021.